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Abstract 
Clinical prediction models provide risk estimates for the presence of disease (diagnosis) or an 
event in the future course of disease (prognosis) for individual patients. Although publications 
that present and evaluate such models are becoming more frequent, the methodology is often 
suboptimal. We propose that seven steps should be considered in developing prediction 
models: 1) consideration of the research question and initial data inspection; 2) coding of 
predictors; 3) model specification; 4) model estimation; 5) evaluation of model performance; 6) 
internal validation; and 7) model presentation. The validity of a prediction model is ideally 
assessed in fully independent data, where we propose four key measures to evaluate model 
performance: calibration-in-the-large, or the model intercept (A); calibration slope (B); 
discrimination, with a concordance statistic (C); and clinical usefulness, with decision curve 
analysis (D). As an application, we develop and validate prediction models for 30-day mortality 
in patients with an acute myocardial infarction. This illustrates the usefulness of the proposed 
framework to strengthen the methodological rigor and quality for prediction models in 
cardiovascular research. 
 
Keywords: Prediction model; non-linearity; missing values; shrinkage; calibration; 
discrimination; clinical usefulness  
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Introduction 
Prediction of the presence of disease (diagnosis) or an event in the future course of disease 
(prognosis) becomes more and more important in the current era of personalised medicine. 
Improvements in imaging, biomarkers and ‘omics’ research lead to many new predictors for 
diagnosis and prognosis.  
Clinical prediction models may combine multiple predictors to provide insight into the 
relative effects of predictors in the model. For example, we may be interested in the 
independent prognostic value of inflammatory markers such as C-reactive protein for the 
clinical course and outcome of an acute coronary syndrome . Clinical prediction models may 
also provide absolute risk estimates for individual patients (2) (3). We focus here on the second 
role of such models, which are commonly developed with regression analysis techniques. 
Logistic regression analysis is most commonly used for the prediction of binary events, such as 
30-day mortality. Cox regression is most common for time-to-event data, such as long-term 
mortality. We focus on prediction models for binary events, and indicate differences with time-
to-event data where most relevant.  
We note that rigorous development and validation of prediction models is important. 
Despite a substantial body of methodological literature and published guidance on how to 
perform prediction research, most models suffer from methodological shortcomings, or are at 
least reported poorly (4) (5) (6) (7). We propose a systematic approach to model development 
and validation, illustrated with prediction of 30-day mortality in patients suffering from an 
acute myocardial infarction. We compare the performance of a simple model (including age 
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only) to a more complex model (including age and other key predictors), which are developed 
either in a small or a large data set.  
 
Case study: prediction of 30-day mortality in acute myocardial infarction 
As an illustrative case study, we consider a cohort of 40,830 patients suffering from an acute 
myocardial infarction who were enrolled in the GUSTO-I trial. The data from this trial have been 
used for many analyses, including the development of a prediction model for 30-day mortality  
and various methodological studies . We consider the development of prediction models in 
patients enrolled in the US (N= 23,034, 1,565 deaths, and a small subset with N=259, 20 
deaths). We validate these models in patients enrolled outside of the US (N=17,796, 1,286 
deaths). The first model only includes age as a continuous, linear term in a logistic regression 
analysis, while a slightly more complex model includes age, Killip class, systolic blood pressure 
and heart rate. Programming code for the analyses is available at 
www.clinicalpredictionmodels.org with R software (R Foundation for Statistical Computing, 
Vienna, Austria, www.r-project.org). The original GUSTO-I model was based on 40,830 patients 
and included 14 predictors . 
 
Seven steps to model development 
We propose seven logically distinct steps in the development of prediction models with regression 
analysis. These steps are addressed below, with more detail provided elsewhere (16). A glossary is 
provided which summarizes definitions and characteristics of terms relevant to prediction model 
development and validation (Appendix). 
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1. Problem definition and data inspection: An important preliminary step is to carefully consider the 
prediction problem. Questions to be addressed include:  
- What is the precise research question? In prediction research, we often are both interested in insight in 
what factors predict the endpoint, and in the pragmatic issue of providing estimates of the absolute risk 
for the endpoint, based on a combination of factors (17). Indeed, in the development of the GUSTO-I 
model, the title mentions ‘Predictors of ..’, suggesting a focus on insight in which prognostic factors 
predict 30-day mortality. The analysis however also describes the development of a multivariable 
prediction model, where a combination of factors predicts absolute risk with a logistic regression 
formula . For insight in the importance of predictors, effects are usually expressed on a relative scale, 
e.g. as an odds ratio (OR). For example, older age is associated with higher 30-day mortality, reflected in 
an OR of 2.3 per 10 years in GUSTO-I, with 95% confidence interval 2.2 – 2.4. In contrast, risk predictions 
are expressed as probabilities on an absolute scale between 0 and 100%. For example, predicted risks 
for 30-day mortality are 2% and 20% for 50 and 80-year-old patients, respectively. Uncertainty can be 
indicated with 95% confidence intervals. This is relevant for relative effects, but may confuse rather than 
help patients and clinicians when provided with absolute risk predictions (18). 
- What is already known about the predictors?  Literature review and close interactions between 
statisticians and clinical researchers are important to incorporate subject matter knowledge in the 
modeling process. The full GUSTO-I data set was of exceptional size, such that many modeling decision 
could reliably be guided by findings in the data. With smaller data sets, drawn from GUSTO-I, 
simulations showed that developed prediction models are unstable and produce too extreme 
predictions (11).  
- How were patients selected? Patient data used for model development are commonly collected for a 
different purpose. The GUSTO-I trial was designed to study the therapeutic effects of streptokinase and 
tissue plasminogen activator. The inclusion criteria for the trial were relatively broad, which implies that 
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the GUSTO-I patients may be reasonably representative for the population of patients with an acute MI. 
We recognize that representativeness is usually a concern when RCT data are used for prognostic 
research, but this may be outbalanced by the superior quality of the data. For prediction of risk in 
current medical practice, the GUSTO-I data are likely outdated, since accrual in the trial was over 20 
years ago.   
Another issue is how we should deal with any treatment effects in prognostic analyses. The 
treatment effect may be of specific interest, and adjustment for baseline prognostic factors has several 
advantages in the estimation of a treatment effect that is applicable to individual patients (19) (20). If 
the focus is on absolute risk prediction, treatment effects have often been ignored, also since they are 
usually relatively small compared to the effects of prognostic factors. In our analyses of the GUSTO-I trial 
we study prognostic effects without consideration of the treatment. 
 For diagnostic prediction models, we note that these should be developed in subjects suspected 
of having a particular condition (3). The selection should mimic the clinical setting, e.g. we may consider 
patients with chest pain suspected of obstructive coronary artery disease for a diagnostic prediction 
model that estimates the presence of obstructive disease . 
- Were the predictors reliably and completely measured? Many data sets are incomplete with respect to 
the values for some potential predictors. By default, patients with any missing value are excluded from 
statistical analyses (complete case analysis, or available case analysis). This is inefficient since available 
information of other predictors is lost. To solve this problem we may fill in best estimates for the missing 
values, exploiting the correlation between variables in the data set (both predictor, endpoint, and 
auxiliary variables such as calendar time and place) (22). Various statistical approaches are available to 
perform such imputation of missing values. Multiple imputation is a procedure to fill in missing values 
multiple times (typically at least 5 times) to appropriately address the randomness of the estimation 
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procedure. We recognize that imputation should be performed carefully, but is usually preferable to a 
complete case analysis (22). 
In GUSTO-I, the collection of baseline data was prospective, since it was an RCT, and the 
definition of all predictors was carefully documented in the trial protocol. This makes us confident 
regarding the quality of the data. It also limited the occurrence of missing values, which were filled in 
with a single imputation procedure considering correlations between predictor variables .   
- Is the endpoint of interest? Hard endpoints are usually preferred, such as 30-day mortality in GUSTO-I, 
which was also the primary endpoint in the trial. Another important issue is the frequency of the 
endpoint, which determines the effective sample size (rather than the total number of patients). The 
GUSTO-I data set had 2851 deaths, which allows for reliable prediction modeling, where a common rule 
of thumb is to require at least ten events per variable (EPV) (2) (12).  
 
2. Coding of predictors: Categorical and continuous predictor variables can be coded in different ways. 
Categories with infrequent occurrence may for instance be collapsed with others. In GUSTO-I, location 
of the infarction might well be coded as anterior versus other, rather than as anterior, inferior, other, 
since a location other than anterior or inferior was infrequent (3% of the patients), and did not lead to a 
better model fit (p=0.30, likelihood ratio test for improving the logistic regression model). 
Continuous predictors can often be modeled as a linear association in a regression model, at 
least as a starting point (23). The interpretation of the relative effect of a predictor requires attention for 
the scale of measurement. For example, the importance of age is easier interpreted when scaled per 
decade (OR 2.3, more than a doubling in odds per decade) than per year (OR 1.09, 9% higher odds per 
year older). Linear terms are obviously not appropriate for predictors with non-linear associations, such 
as a J-shape or U-shape. Such shapes can efficiently be modeled using restricted cubic splines (2) or 
fractional polynomials (23). These functions provide flexibility but use only few extra regression 
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coefficients. We emphasize that continuous predictors should not be dichotomized (categorization as 
below versus above a certain cut-off) in the model development phase, since valuable information is lost 
(24). In a later phase we may search for a user-friendly format of the prediction model and categorize 
some predictors (e.g. in 3, 4, or 5 categories), if the loss of predictive information is limited . 
 
3. Model specification: Various strategies may be followed to choose predictors for inclusion in the 
prediction model. Stepwise selection methods are widely used to reduce a set of candidate predictors, 
but have many disadvantages. In particular when the numbers of events are low, the selection is 
instable, the estimated regression coefficients are too extreme, and the performance of the selected 
model is overestimated (2) (10) (16) (26). In the small sample of 259 patients, age and systolic blood 
pressure were statistically significant predictors, but Killip class (p=0.31) and heart rate (p=0.92) were 
not. In the total GUSTO-I data set, the sample size was large enough to rely on statistical testing for 
identification of predictors. All 14 predictors selected for the GUSTO-I model had p-values below 0.01 . 
A related issue is how researchers should deal with assumptions in regression models, such as 
that the effect of one predictor is the same irrespective of the value of other predictors. This additivity 
assumption can be relaxed by including statistical interaction terms (2). In the full GUSTO-I data set, one 
such term was included in the prediction model (age*Killip class) . It appeared that with higher age, the 
prognostic effect of higher Killip class was less strong than for younger patients. For time to event data, 
the Cox model assumes proportionality of effects, which can be tested with interaction terms including 
time (2). 
We note that iterative cycles of testing of the importance of predictors, assumptions in the 
model, and adaptation may lead to a model that fits the data well. But such a model may provide 
predictions that do not generalize to new subjects outside the data under study (“overfitting”) (2) (16). A 
simple, robust model may not fit the data perfectly, but should be preferred to an overly fine-tuned 
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model for the specific data under study. Similarly, predictor selection should usually consider clinical 
knowledge and previous studies rather than solely rely on statistical selection methods (2) (16). 
 
4. Model estimation: Once a model is specified, regression coefficients need to be estimated. For logistic 
and Cox regression models, we commonly estimate coefficients with maximum likelihood (ML) methods. 
Some modern techniques have been developed that aim to limit overfitting of a model to the available 
data, such as statistical shrinkage techniques (27), penalized ML estimation (28), and the least absolute 
shrinkage and selection operator (LASSO) (11) (29). For the model estimated in 259 patients, we found a 
shrinkage factor of 0.82. The regression coefficients should be multiplied by that value to provide more 
reliable predictions for new patients.  
 
5. Model performance: For a proposed model, researchers need to determine the quality. Several 
performance measures are commonly used, including measures for model calibration and 
discrimination. We discuss these and measures for clinical usefulness with model validation.  
 
6. Model validity: It is important to separate internal and external validity. Internal validity of a 
prediction model refers to the validity of claims for the underlying population that the data originated 
from (‘reproducibility’) (30). Internal validation may especially address the stability of the selection of 
predictors, and the quality of predictions. Using a random sample for model development, and the 
remaining patients for validation (‘split sample validation’) is a common, but suboptimal form of internal 
validation (13). Better methods are cross-validation and bootstrap resampling, where samples are 
drawn with replacement from the development sample (2). In the small sample of 259 patients, 
bootstrapping indicated that the discriminative ability was expected to decrease from 0.82 to 0.78 in 
new patients. Such internal validation should always be attempted when developing a prediction model.  
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External validity refers to generalizability of claims to ‘plausibly related’ populations (30). 
External validation is commonly considered a stronger test for prediction models than internal 
validation, since it addresses transportability rather than reproducibility. External validity may be 
evaluated by studying patients who were more recently treated (temporal validation), from other 
hospitals (geographic validation), or treated in fully different settings (strong external validation) (30) 
(31). 
 
7. Model presentation: As a final step we propose to consider is the presentation of a prediction model, 
such that it best addresses the clinical needs. Regression formulas can be used, such as the formula 
published with the GUSTO-I model . Many paper-based alternatives are available for easy applicability of 
a model, including score charts and nomograms (2). A recent trend is to present prediction models as 
web-based calculators, or as apps for mobile phones and tablets. In the future, prediction models may 
well be embedded in decision aids and in electronic patient records to support clinical decision-making. 
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An ABCD for model validation 
Whatever the method used to develop a model, one could argue that validity is all that matters 
(7). We propose four key measures in the assessment of the validation of prediction models, 
related to calibration, discrimination and clinical usefulness (32) (33) (34) (35). The measures 
are illustrated by studying the external validity of the models developed in 259 or 23,034 
patients enrolled in GUSTO-I in the US and tested in 17,796 GUSTO-I patients from outside the 
US. 
 
A, Alpha: Calibration-in-the-large 
Calibration refers to the agreement between observed endpoints and predictions (33). For 
example, if we predict a 5% risk that a patient will die within 30 days, the observed proportion 
should be approximately 5 deaths per 100 with such a prediction. Calibration can well be 
assessed graphically, in a plot with predictions on the x-axis and the observed endpoint on the 
y-axis (Figure 1). The observed values on the y-axis are 0 or 1 (dead/alive), while the predictions 
on the x-axis range between 0 and 100%. To visualise the agreement between the observed 
and predicted values, smoothing techniques can well be used to depict the association (36). We 
can also plot the observed proportions of death for groups of patients with similar predicted 
risk , for instance by deciles of predictions. Considering such groups with their deviations from 
the ideal line makes the plot a graphical illustration of the often used Hosmer-Lemeshow 
goodness-of-fit test. We do not recommend this test for assessment of calibration. It does not 
indicate the direction of any miscalibration and only provides a p-value for differences between 
observed and predicted endpoints per group of patients (commonly deciles) (33). Such 
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grouping is arbitrary and imprecise, and p-values depend on the combination of the extent of 
miscalibration and sample size. Rather, we emphasize the older recalibration idea as proposed 
by Cox in 1958 (37). Perfect predictions should be on the ideal line, described with an intercept 
alpha (‘A’) of 0 and slope beta (‘B’) of 1. The log odds of predictions are used as the predictor of 
the 0/1 outcome, or the log(hazard) for time to event outcomes (37) (38). Imperfect calibration 
can be characterized by deviations from these ideal values. 
The intercept A relates to calibration-in-the-large, which compares the mean of all 
predicted risks with the mean observed risk. The parameter hence indicates the extent that 
predictions are systematically too low or too high. At model development observed incidence 
and mean predicted risk are equal for regression models, and assessment of calibration-in-the-
large makes no sense. At external validation, calibration-in-the-large problems have often been 
found, for example for the Framingham model in multiple ethnic groups (39), or the 
Framingham variant developed by NICE for the UK (31). If we test the prediction model 
developed in 23,034 US patients outside of the US, we note a slightly higher mortality (A=0.07, 
p=0.38; equivalent to an odds ratio of non-US vs US of exp(0.07) = 1.07, right panel of Figure 1). 
Note that no intercept is calculated if a Cox model is used at external validation (35). Other 
types of models, such as Weibull regression models, can be used to assess calibration-in-the-
large for survival models (40). 
 
B, Beta: Calibration slope 
The calibration slope B is often smaller than 1 if a model was developed in a relatively small 
data set. For the model based on 259 patients, the slope was 0.70 among the 17,796 non-US 
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patients, in line with what was expected at internal validation (shrinkage factor 0.82). For the 
model based on 23,034 patients, B was close to one at internal validation by cross-validation or 
bootstrapping , as well as at external validation in non-US patients (slope 0.99, p=0.55 for 
comparison to slope=1, Figure 1).  
 
C, Concordance statistic: discrimination  
Discrimination refers to the ability of the model to distinguish a patient with the endpoint 
(dead) from a patient without (alive). A better discriminating model has more spread between 
the predictions than a poorly discriminating model (34). Indeed, a model that predicts for all 
subjects the same predicted risk equal to the incidence shows perfect calibration, but is useless 
since it does not discriminate between patients. A validation plot showing a wide spread 
between predictions as a histogram, or between deciles of predicted risk, indicates a good 
discriminating model (Figure 1). Discriminative ability is commonly quantified with a 
concordance (c) statistic. For a binary endpoint, c is identical to the area under the receiver 
operating characteristic (ROC) curve, which plots the sensitivity (true positive rate) against 1 – 
specificity (false positive rate) for consecutive cut-offs for the predicted risk. For a time-to event 
endpoint, such as survival, the calculation of c may be affected by the amount of incomplete 
follow-up (censoring).  We note that the c statistic is insensitive to systematic errors in 
calibration, and considers the rather artificial situation of classification in a pair of patients with 
and without the endpoint. 
 In GUSTO-I, the c statistic indicates the probability that among two patients, one dying 
before 30 days, and one surviving, the patient bound to die will have a higher predicted risk 
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than the surviving patient.  The more complex prediction model had c statistics over 0.8 (0.813 
[0.802-0.824] and 0.812 [0.800-0.824] at internal and external validation, respectively). This 
performance was much better than a model which only included age (0.75 at external 
validation, left panel in Figure 1). With development in only 259 patients, the apparent c 
statistic was 0.82, but 0.78 at internal validation, and 0.80 [0.79-0.82] at external validation. 
This illustrates that the availability of a smaller data set decreases model performance at 
external validation. 
 
D: Decision curve analysis 
Calibration and discrimination are important aspects of a prediction model, and consider the 
full range of predicted risks. However, these aspects do not assess clinical usefulness, i.e. the 
ability to make better decisions with a model than without (33). If a prediction model aims to 
guide treatment decisions, a cut-off is required to classify patients as either low risk (no 
treatment) or high risk (treatment is indicated). The cut-off is a decision threshold. At the 
threshold, the likelihood of benefit, e.g. reduced mortality as a result of thrombolytic therapy, 
exactly balances the likelihood of harm, e.g. bleeding risk and financial costs. A threshold value 
of e.g. 2% indicates that death of a non-treated patient is 98:2=49 times worse than the 
complications of a bleeding incident and costs of an unnecessarily treated patient. It is usually 
difficult to define a threshold since empirical evidence for the relative weight of benefits and 
harms is often lacking. Further, some patients may be prepared to take higher risk for a possible 
benefit than others. It is therefore advised to consider a range of thresholds when quantifying 
the clinical usefulness of a prediction model (41).  
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Once a threshold has been applied to classify patients as low versus high risk, sensitivity 
and specificity are often used as measures for usefulness. Finding an optimal balance between 
these is again possible with consideration of harms and benefits of treatment, in combination 
with the incidence of the endpoint. The sum of sensitivity and specificity can only be used as a 
naïve summary indicator of usefulness, since such a sum ignores the relative weight of true 
positives (considered in sensitivity) and false positives (considered in 1 – specificity) (42). 
Recently proposed and more appropriate summary measures include the net benefit 
(NB) (41). This measure is consistent with the use of an optimal decision threshold to classify 
patients (43). The relative weight of harms and benefits is used to define the threshold, and is 
used to calculate a weighted sum of true minus false positive classifications (41).  
For GUSTO-I, we first note that the 7% overall 30-day mortality implies a maximum NB 
of 7%. This is obtained if we use a threshold of 0%. All patients are then candidates for tPA 
treatment since we assume no harm of treatment. If we appreciate that treatment involves 
some harm, the optimal decision threshold is above 0%. We find that treatment decision 
making on the basis of risk predictions from a model would give a slightly higher net benefit 
than treating everyone. For example at a threshold of 2%, we have 1225 true positive 
classifications (candidates for treatment, and died), but also 11,192 false positive classifications 
(candidates for treatment, but survived) among the 17,796 non-US patients. The net benefit is 
calculated as (1225 – 2/98 * 11,192) / 17,796 = 5.6% (Figure 2). This is only slightly better than 
treating all, where NB = (1286 – 2/98 * 16,510) / 17,796 = 5.3%, since 1286 died and 16,510 
survived overall. The difference is 0.3%. This implies that for every 1000 patients where we 
apply the prediction model, 3 extra true positives are identified without increasing the false 
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positive rate. The net benefit was higher for a higher threshold, such as 5% (19 per 1000 extra 
net true positives). Based on age only, the net benefit was virtually absent for a 2% decision 
threshold (0.04%, Figure 2), and in-between for a model based on only 259 patients (0.2%, 
Figure 2). Figure 2 illustrates that using more prognostic information than age increases the 
clinical usefulness of a model, and that a larger sample size leads to a better performing model. 
Documentation and software for decision-curve analysis is publicly available 
(www.decisioncurveanalysis.org), considering both binary and time-to-event end points. 
 
Concluding remarks 
We discussed seven steps to reliably develop a prediction model, and four measures that are 
important at model validation. There are many details to consider for each development and 
validation step, which are discussed in the methodological literature. Involvement of statistical 
experts is usually required to well develop or validate a prediction model. We provided an 
illustration on predicting 30-day mortality in patients with an acute myocardial infarction. The 
exceptional size of the US part of the GUSTO-I trial implied that overfitting was not relevant. 
Overfitting is a key problem in many prediction models. This is either because the number of 
events is small, as illustrated with the substudy in 259 patients, or because many potential 
predictors are studied, such as in genetic or other ‘omics’ analyses. 
At model validation, calibration, discrimination and clinical usefulness should be 
considered. A validation graph such as Figure 1 (or a variant with a ‘calibration belt’ (44)) is an 
important summary tool. We furthermore recognize that a key question is nowadays how we 
can quantify an increase in predictive ability by new markers. For markers we may consider 
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changes in the A, B, C and D measures related to calibration, discrimination and clinical 
usefulness. Miscalibration of predictions is common at external validation (A different from 0, B 
< 1), but we would expect this to be similar when adding a marker to a model. Some 
performance measures, such as the Net Reclassification Improvement require well calibrated 
predictions to be meaningful (45) (46). Discrimination (C) only shows modest increases for most 
currently available markers in cardiology (47). Some researchers have blamed the c statistic as 
being insensitive. One might argue that we should merely accept that markers with statistically 
significant effects, but with a modest relative effect size, will not impact tremendously on 
identifying those with or without the endpoint (48). Cost-effectiveness analyses should 
eventually guide us on the question whether an increase in performance is important enough 
to measure an additional marker in clinical practice . Measures for clinical usefulness such as 
the net benefit (which may be shown in decision curves, D) are easy to calculate, increasingly 
used, and give a first impression of effectiveness in terms of potentially better patient 
outcomes (43). The net reclassification improvement (NRI) is very similar in behavior to 
measures for discrimination (50). We hence did not discuss this quite popular measure in detail 
here. A fierce debate is ongoing on the relevance of the NRI in the evaluation of the predictive 
value of markers (42) (46) (51). 
We see a role for our proposed framework to support methodological researchers who 
develop and validate prediction models. More importantly, clinical researchers may use the 
framework to systematically and critically assess a publication where a prediction model is 
developed or validated. We anticipate that following the framework, admittedly with room for 
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refinements, will strengthen the methodological rigor and quality of prediction models in 
cardiovascular research. 
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Table 1 Illustration of seven steps for developing a prediction model with the GUSTO-I data 
(n=40,830)   
Step Specific issues GUSTO-I model 
1. Problem definition and 
data inspection 
 
Aim: predictors or predictions? 
 
 
Selection, predictor definitions 
and completeness, endpoint 
definition 
Aim is both insights in which 
predictors are important and to 
provide individualized risk 
predictions 
Prospective data collection in a 
randomized trial with a hard 
endpoint (30-day mortality). Missing 
predictor values were imputed. 
2. Coding of predictors Continuous predictors 
 
Combining categorical predictors 
Extensive checks of transformations 
for continuous predictors 
Categories kept separate, e.g. for 
location of infarction 
3. Model specification Selection of main effects? 
 
Assessment of assumptions? 
Stepwise selection; appropriate 
because of very large sample size 
Additivity checked with interaction 
terms; one included (age*Killip class) 
4. Model estimation Shrinkage included? Not necessary 
5. Model performance Appropriate measures used? Calibration and discrimination, but 
no indicators of clinical usefulness 
6. Model validation Internal validation including 
model specification and 
estimation? 
Bootstrap and 10 fold cross-
validation 
7. Model presentation Format appropriate for audience No; complex formula in appendix 
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Table 2. Overview of four measures (ABCD) for model performance. 
Aspect Measure Visualisation Characteristics 
Calibration A: alpha 
Calibration-in-the-large 
Calibration plot Intercept in plot; compares mean 
observed with mean predicted 
 B: beta 
Calibration slope 
 Regression slope in plot; related to 
shrinkage of regression coefficients 
Discrimination C statistic ROC curve Interpretation for a pair of subjects 
with and without the endpoint 
Clinical usefulness Decision curve analysis 
Net benefit 
Decision curve Net true positive classification rate by 
using a model over a range of 
thresholds 
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Appendix 
Glossary of terms relevant to prediction model development and validation 
Term Definition Characteristics  
Continuous predictors   
Restricted cubic 
splines 
Smooth functions with linear tails.  
 
One to three extra regression coefficients 
are sufficient to adequately model most 
non-linear shapes.(2) 
Fractional polynomials A combination of 1 or 2 polynomial 
transformations such as x2 + x-1, with 
powers from the set (-3, -2, -1,-
0.5,0,0.5,1,2,3). 
An automatic search can find 
transformations to adequately model non-
linear shapes, including reciprocal, 
logarithm, square root, square and cubic 
transformations.(23) 
Missing values   
Complete case analysis Analysis that considers patients with 
complete information on all predictors 
and the endpoint available 
Performed by default in statistical packages, 
but inefficient.(22) 
Multiple imputation Fill in missing values multiple times to 
allow for analyses of completed data sets 
Statistically efficient, but relies on 
assumptions of the missing value generating 
mechanism, and a correct imputation 
model.(22) 
Reliable estimation   
Events per variable The number of patients with the event of 
interest divided by the number of 
predictor variables considered. 
Indicates effective sample size, which is 
lower than the total number of patients. 
The count of predictor variables should 
include all regression coefficients 
considered for all candidate predictors (not 
only the predictors that are finally selected 
for a prediction model).(2) 
Stepwise selection Procedure to eliminate candidate 
predictors that are not relevant to making 
predictions 
Reduces the set of predictors. Many variants 
of stepwise selection are possible, all with 
disadvantages especially in small data 
sets.(16) 
Shrinkage Reduce regression coefficients towards 
zero, such that less extreme predictions 
are made. 
Improves predictions from models, 
especially in small data sets. Specific 
methods include penalized estimation, such 
as the LASSO.(11) 
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Validation   
Internal validation Assesses the validity of claims for the 
underlying population where the data 
originated from (‘reproducibility’)  
Common methods are cross-validation and 
bootstrap resampling.(2) 
External validation Assesses the validity of claims for 
‘plausibly related’ populations 
(‘generalizability, or ‘transportability’). 
Study patients who were more recently 
treated (temporal validation), from other 
hospitals (geographic validation), or treated 
in fully different settings (strong external 
validation).(30) 
Evaluation of predictions  
Calibration Agreement between observed and 
predicted risks  
Calibration is usually near perfect at model 
development, and especially of interest at 
external validation. (16) 
Discrimination Ability to distinguish a patient with the 
endpoint from a patient without  
Discrimination is a key aspect of model 
performance, but the concordance statistic  
(‘C’) refers to the artificial situation of a 
considering a pair of patients.(33) 
Evaluation of classifications  
Decision threshold Cut-off for a predicted risk to define a 
low and a high risk group 
The optimal threshold is defined by the 
balance between the harm of a false-
positive classification and the benefit of a 
true-positive classification.(41)  
Sensitivity (specificity) Probability of true-positive (true-
negative) classification among those 
with (without) the end point 
Traditional measures to quantify 
classification performance, conditional on 
knowing the endpoint.(33) 
Net benefit A weighted sum of true-positive and 
false-positive classifications 
Novel measure to quantify classification 
performance, taking a decision-analytic 
perspective.(41) 
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Figure 1 
Validation plots for clinical prediction models applied in 17,796 patients enrolled in GUSTO-I 
outside the US. The models contained the predictors age (left panel), or age plus Killip class, 
blood pressure, and heart rate (right panels, with n=259 or n=23,034 US patients for model 
development). 
A: calibration-in-the-large, calculated as the logistic regression model intercept given that the 
calibration slope equals 1; B: calibration slope in a logistic regression model with the linear 
predictor as the sole predictor; C: c statistic indicating discriminative ability. 
Triangles represent deciles of subjects grouped by similar predicted risk. The distribution of 
subjects is indicated with spikes at the bottom of the graph, stratified by endpoint (deaths 
above the x-axis, survivors below the x-axis). 
 
 
Figure 2 
Decision curves for the prediction models applied in 17,796 patients enrolled in GUSTO-I 
outside the US. Solid line: Assume no patients are treated, net benefit is zero (no true positive 
and no false positive classifications); Grey line: assume all patients are treated; Dotted lines: 
patients are treated if predictions exceed a threshold, with 30-day mortality risk predictions 
based on age only, or a prediction model with age, Killip class, blood pressure, and heart rate, 
developed in n=259 or n=23,034 US patients. The graph gives the expected net benefit per 
patient relative to no treatment in any patient (“Treat none”). The threshold defines the weight 
w for false-positive (FP, treat while patient did not die) versus true-positive (TP, treat a patient 
who died) classifications. For example, a threshold of 2% implies that FP classifications are 
valued at 2/98 of TP classifications, and w is 0.02 /(1 – 0.02) = 0.0204. The clinical usefulness of 
a prediction model can then be summarized as: NB = (TP - w FP)/N, where N is the total number 
of patients (41). 
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